Afzal MZ - Search Results

1

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Afzal MZ, Mercado RR, Shirai K. Afzal MZ, et al. J Immunother Cancer. 2018 Jul 2;6(1):64. doi: 10.1186/s40425-018-0375-1. J Immunother Cancer. 2018. PMID: 29966520 Free PMC article.

2

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.

Afzal MZ, Mabaera R, Shirai K. Afzal MZ, et al. J Immunother Cancer. 2018 Feb 12;6(1):13. doi: 10.1186/s40425-018-0322-1. J Immunother Cancer. 2018. PMID: 29433557 Free PMC article.

3

Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.

Afzal MZ, Shirai K. Afzal MZ, et al. Melanoma Res. 2018 Aug;28(4):341-347. doi: 10.1097/CMR.0000000000000459. Melanoma Res. 2018. PMID: 29750753

4

A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.

Afzal MZ, Dragnev K, Shirai K. Afzal MZ, et al. J Thorac Dis. 2018 Jun;10(6):3575-3584. doi: 10.21037/jtd.2018.06.08. J Thorac Dis. 2018. PMID: 30069355 Free PMC article.

5

Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.

Afzal MZ, Shirai K. Afzal MZ, et al. J Immunother. 2019 May;42(4):136-141. doi: 10.1097/CJI.0000000000000265. J Immunother. 2019. PMID: 30933044

6

An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.

Afzal MZ, Dragnev KH, Shirai K. Afzal MZ, et al. Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09. Ann Transl Med. 2019. PMID: 31032332 Free PMC article. No abstract available.

7

Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.

Afzal MZ, Sarwar T, Shirai K. Afzal MZ, et al. J Immunother. 2019 Sep;42(7):251-264. doi: 10.1097/CJI.0000000000000272. J Immunother. 2019. PMID: 31145229

8

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.

Afzal MZ, Dragnev K, Sarwar T, Shirai K. Afzal MZ, et al. Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645894 Free PMC article.

9

Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.

Cao Y, Afzal MZ, Shirai K. Cao Y, et al. Among authors: afzal mz. BMJ Case Rep. 2021 Aug 20;14(8):e243713. doi: 10.1136/bcr-2021-243713. BMJ Case Rep. 2021. PMID: 34417242 Free PMC article.

10

Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.

Cao Y, Afzal MZ, Shirai K. Cao Y, et al. Among authors: afzal mz. J Thorac Dis. 2021 Aug;13(8):4668-4677. doi: 10.21037/jtd-21-150. J Thorac Dis. 2021. PMID: 34527308 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters